Thursday, April 21, 2011

Eye Love Serendipity

I'm sure most of us would agree that some of the best things in life happen by accident. Indeed, some of the greatest scientific discoveries were the fruits of good fortune. Penicillin, vulcanized rubber, and even gravity were all accidental findings.
But these discoveries all pale in comparison to pharma company, Allergan's newest serendipitous breakthrough! (yes, I'm being mildly sarcastic)

In 2001, Allergan produced an eye drop named Lumigan (bimatoprost ophthalmic solution 0.03%). It's primary function was to decrease the pressure inside the eye in patients who had, or were at risk for, Glaucoma. Lumigan was very successful, but it had some interesting side effects.

Doctors noticed that patients were returning to clinics with very specific complaints. Their eyelashes were, all of a sudden, growing at exponential rates. So significant was the growth of these cilia, in fact, that eye doctors were actually having to trim some patients' lashes!

It didn't take long for someone at Allergan (I'm sure it was a woman) to realize how huge this could be. A few years of "research" later, plus a lovely new spokeswoman (Brooke Shields) and voila! In 2008, we have a product named Latisse, which just happens to be bimatoprost ophthalmic solution 0.03%. (How did that take 7 years??)


Anyway, Latisse promises (and, for the most part, delivers) longer, thicker eyelashes. You simply dab a little bit along the upper eyelash margin once a day for 16 weeks (that's 112 days to be exact) and before you know it you'll be a modern day Elizabeth Taylor (more on her later).

Check out the Latisse website (www.latisse.com) for their FAQ section which has answers to questions including side effects, application, and where to find this miracle drug.

Here is one of the more important question and answers from the website:
Question: Does Claire Danes really use LATISSE®?
Answer: Yes. Claire Danes is using LATISSE® and is happy with her results.

Well I'll be damned!! Sign me up then! 

---

No comments:

Post a Comment